Background: The comparison between endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) and EUS guided fine needle biopsy (FNB) in sampling pancreatic masses is still controversial.
Introduction
Pancreatic cancer is characterized by a poor prognosis, with an overall 5-year survival rate of 5% to 6% and a median survival of 3 to 5 months after diagnosis of metastatic disease. [1] Thus, rapid and accurate pathological diagnosis of pancreatic masses is important to direct subsequent clinical management. Currently, endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) is the standard method for tissue diagnosis of pancreatic masses, with a reported sensitivity of 85% to 95%, specificity of 95% to 98% and diagnostic accuracy of 78% to 95%. [2, 3] The diagnostic failures are usually caused by inadequate samples, inexperience of the endoscopist, and necrotic, or fibrotic tumors in which viable cells are difficult to obtain. [4] Recently, a new core biopsy needle, which is equipped with a side opening and a reverse bevel, has been developed to improve the sample quality. Sampling with this new needle is referred as EUS guided fine needle biopsy (EUS-FNB). Several randomized controlled trials (RCTs) have compared EUS-FNA and EUS-FNB in sampling pancreatic masses, but reached inconsistent results. The meta-analysis by Wang et al [5] found that EUS-FNB showed a comparable accuracy to EUS-FNA in diagnosing pancreatic masses. However, it ignored several newly published studies, especially the largescale RCT by Chen et al, [6] in which EUS-FNB showed a higher accuracy than EUS-FNA in diagnosing pancreatic masses. Thus, we conducted an update meta-analysis of RCTs to compare the efficacy and safety of EUS-FNA and EUS-FNB in sampling pancreatic masses.
Methods

Search strategy
The databases of PubMed and Web of Science were searched for relevant studies published up to October 28, 2017, using the key words including: "endoscopic ultrasound," "EUS," "fine needle aspiration," "EUS-FNA," "fine needle biopsy," "core biopsy," "EUS-FNB," "pancreas," and "pancreatic". Studies in languages other than English or Chinese were excluded. Moreover, we also reviewed the references of related studies, reviews and metaanalyses for undetected studies. This study was approved by the ethics committee of The Central Hospital of Enshi Autonomous Prefecture.
Study selection and exclusion
All the studies were reviewed independently by 2 investigators. Studies were included if they satisfied the following criteria: patients with the presence of pancreatic masses revealed by computed tomography (CT) and/or magnetic resonance imaging (MRI) and/or EUS; RCTs; compared EUS-FNA and EUS-FNB in sampling pancreatic masses; included at least one of the following as outcome measures: diagnostic adequacy, diagnostic accuracy, mean number of needle passes required for diagnosis, adverse events or complications, and technical success. The exclusion criteria were as follows: reviews, case-reports, pediactric or animal studies, non-RCTs, and studies without full-text or sufficient data.
Data extraction and quality assessment
The following information was extracted from each included study: authors, publication year, area, study duration, number of cases, sampling type (EUS-FNA or EUS-FNB), needle size, age, mass size, suction method, sample examination, follow-up for final diagnosis, diagnostic adequacy, diagnostic accuracy, mean number of needle passes required for diagnosis, adverse events or complications, and technical success. The quality of included studies was assessed using the Cochrane collaboration's tool for assessing the risk of bias, with the following domains: random sequence generation, allocation concealment, binding of participants and personnel, binding of outcomes assessment, incomplete outcome data, and selective reports. [7] Any disagreement in data abstraction and quality evaluation was solved by discussion.
Statistical analysis
All data analyses were realized with Review Manager 5.2 (RevMan, The Nordic Cochrane Center, The Cochrane Collaboration, 2012). For dichotomous data, odds ratios (OR) with 95% confidence intervals (CI) were used to report the risk estimates following the Mantel-Haenszel method. [8] For continuous data, mean differences (MD) and 95% CI were adopted by the method of Inverse Variance. The heterogeneity between studies was estimated by Q test and I 2 statistic. I 2 >50% represented substantial heterogeneity, and a random-effects analysis was conducted. Otherwise, a fixed-effects model was used. Egger's test was used to detect publication bias. All tests were sided with a significance level of 0.05.
Results
Characteristics of included studies
Finally, 11 studies were included into this meta-analysis, with a total of 694 cases for EUS-FNA and 688 cases for EUS-FNB. [6, 9, [10] [11] [12] [13] [14] [15] [16] [17] [18] The characteristics of included studies were listed in Table 1 . In FNA, the needle sizes were 22G (n = 10) and 25G (n = 3), and the most common needle was EchoTip of Cook Medical (n = 8), followed by Expect of Boston Scientific (n= 2), and EZShot2 of Olympus (n = 1) (Table S1 , http://links.lww.com/ Noh et al) used both needles in all patients, while the other 6 studies used either FNA or FNB in each patient. More than half of the studies applied rapid on-site evaluation which could ascertain sample adequacy for further analysis. The final diagnosis was based on histology, cytology and immunohistochemistry. Seven studies also had a follow-up of at least 6 months for the final diagnosis. In quality assessment, all included studies were at low risk of selection bias, detection bias, attrition bias and reporting bias, but at high risk of performance bias as no endoscopist was blinded to the type of needle in use ( Figure S1 , http://links.lww. com/MD/C179).
Specimen adequacy
Seven studies compared the specimen adequacy between FNA and FNB (Fig. 1) . FNB had a better specimen adequacy than FNA in sampling pancreatic masses (OR: 1.83, 95% CI: 1.27-2.64;
Egger's test detected no significant publication bias (P = .294).
Diagnostic accuracy
Ten studies compared the diagnostic accuracy between FNA and FNB (Fig. 2 ). FNB showed a higher accuracy than FNA in diagnosing pancreatic masses (OR: 1.62, 95% CI: 1.17-2.26; I 2 = 17%). In the 7 studies with a follow-up of at least 6 months, FNB also showed a higher accuracy (OR: 1.73, 95% CI: 1.21-2.48; I 2 = 5%). Egger's test detected no significant publication bias (P = .644).
Number of needle passes required for diagnosis
Five studies compared the mean number of needle passes required for diagnosis between FNA and FNB (Fig. 3) . FNB had a fewer number of needle passes than FNA in sampling pancreatic masses (MD: À0.69, 95% CI: À1.18 to À0.20; I 2 = 92%). Egger's test detected no significant publication bias (P = .838).
Complications
Ten studies compared the complications between FNA and FNB (Fig. 4) . The 2 groups showed no significant difference in the www.md-journal.com incidence of complications (OR: 1.01, 95% CI: 0.27-3.78; I 2 = 0%).
Technical success
Nine studies compared the technical success between FNA and FNB (Fig. 5) . The 2 groups showed no significant difference in the rate of technical success (OR: 0.13, 95% CI: 0.02-1.07; I 2 = 0%).
Discussion
Currently, EUS-FNA is considered to be the gold standard for EUS-guided sampling of pancreatic masses. However, it still has First of all, EUS-FNA samples relatively a small amount of tissue specimens, and unable to provide core tissue with preserved architecture which is essential for histological diagnosis of pancreatic masses. For example, cytological analysis alone may not diagnose certain neoplasms like stromal cell tumors, lymphomas, and well-differentiated adenocarcinomas. [19] To obtain more specimens for an accurate diagnosis, it is inevitable to increase the number of needle passes which can lead to an increasing risk of adverse events. Moreover, the success of EUS-FUA is also greatly influenced by the presence of an on-site histopathologist or cytopathologists, as well as an experienced endoscopist.
In order to overcome some of these limitations and to improve diagnostic accuracy, EUS-FNB was developed to promote the collection of core tissue. Compared with FNA, FNB was characterized by a core trap which could reduce the number of needle passes required to establish a diagnosis, particularly a histological diagnosis. In our meta-analysis, we also found FNB group required fewer needle passes and obtained more specimen than FNA group. This might explain the higher diagnostic accuracy in FNB group. In the aspects of complications and technical success, no significant difference was found between the 2 groups. In general, EUS-FNB showed superiority to EUS-FNA in sampling pancreatic masses.
The recent meta-analysis by Khan et al [20] compared EUS-FNA and EUS-FNB in the diagnostic yield and the value of onsite cytopathological assessment. No significant difference was found in diagnostic adequacy (RR: 0.99, 95% CI: 0.95-1.03; n = 12), as well as for pancreatic lesions (RR: 0.99, 95% CI: 0.90-1.08; n = 9). Another recent meta-analysis by Wang et al [5] compared EUS-FNA and EUS-FNB in sampling pancreatic masses, and the diagnostic accuracy was comparable in FNA and FNB group (RR: 0.72, 95% CI: 0.49-1.07; n = 7). However, there was a trend toward FNB showing a higher diagnostic accuracy in sampling pancreatic masses than FNB. We thought this might contribute to the limited number of included studies, and the diagnostic accuracy might be different between FNA and FNB. After including 3 newly published studies, we found a higher diagnostic accuracy in EUS-FNB. Thus, we conducted this metaanalysis, and wanted the finding to be a reference for clinical practice in the future.
Several limitations in this study also need to be considered. First, all studies were at high risk of performance bias. Second, there was obvious heterogeneity in the meta-analyses of needle passes which might be caused by limited number of included studies. Third, the needles in Aadam et al study were not in the same size between the FNA and FNB groups.
